Linked Life Data

6478451

Source:http://linkedlifedata.com/resource/pubmed/id/6478451

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
9
pubmed:dateCreated
1984-11-1
pubmed:abstractText
Twenty previously untreated patients with advanced colorectal carcinoma were treated with acivicin given in a 5-day iv schedule at a starting dose of 15 mg/m2, escalating to 26 mg/m2. Therapy was repeated every 3 weeks. Nineteen patients were evaluable for toxicity, which was mild and tolerable overall. Hematological toxicity was minimal, with only one patient developing severe myelosuppression at the starting dose. Nonhematological toxicity was also mild to moderate, occurring in 70% of the patients. Nausea, vomiting, and stomatitis were the most common side effects. CNS toxicity was moderate and occurred in 55% of the patients. Some patients found these symptoms distressing, although the treatment had to be discontinued in only one patient. There were no objective responses among 17 patients evaluable for response. This study indicates that acivicin given in a 5-day schedule is well-tolerated overall.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0361-5960
pubmed:author
pubmed:issnType
Print
pubmed:volume
68
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1121-3
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed:year
1984
pubmed:articleTitle
Phase II study of acivicin in colorectal carcinoma: a National Cancer Institute of Canada study.
pubmed:publicationType
Journal Article